Quantbot Technologies LP Makes New $634,000 Investment in Haleon plc (NYSE:HLN)

Quantbot Technologies LP bought a new stake in Haleon plc (NYSE:HLN) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 66,443 shares of the company’s stock, valued at approximately $634,000.

Several other hedge funds and other institutional investors also recently modified their holdings of HLN. Sierra Ocean LLC acquired a new position in Haleon during the 4th quarter worth approximately $26,000. Versant Capital Management Inc grew its stake in shares of Haleon by 2,029.1% during the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after buying an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Haleon during the fourth quarter worth $35,000. Toronto Dominion Bank lifted its stake in shares of Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock valued at $38,000 after acquiring an additional 3,470 shares during the last quarter. Finally, Spire Wealth Management acquired a new stake in shares of Haleon during the 4th quarter valued at $39,000. Institutional investors own 6.67% of the company’s stock.

Analyst Ratings Changes

HLN has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Haleon in a report on Monday, March 3rd. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Morgan Stanley downgraded shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. HSBC restated a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Finally, Hsbc Global Res lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Six investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $10.95.

Haleon Stock Performance

Shares of HLN stock opened at $10.12 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. Haleon plc has a one year low of $7.99 and a one year high of $10.80. The business’s 50 day simple moving average is $9.92 and its 200 day simple moving average is $9.88. The stock has a market capitalization of $45.81 billion, a PE ratio of 29.76, a PEG ratio of 2.82 and a beta of 0.25.

Haleon (NYSE:HLN) last posted its quarterly earnings data on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The company had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. As a group, research analysts forecast that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The firm also recently declared a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be issued a dividend of $0.1166 per share. This is an increase from Haleon’s previous — dividend of $0.05. This represents a yield of 1.6%. The ex-dividend date of this dividend is Friday, April 25th. Haleon’s dividend payout ratio (DPR) is presently 58.97%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.